This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cytokine release syndrome
Journal for ImmunoTherapy of Cancer Open Access 15 June 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6: 224ra25.
Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509–1518.
Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012; 18: 1859–1866.
O'Donnell P, Raj K, Pagliuca A . High fever occurring 4 to 5 days post-transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-transplant cyclophosphamide as prophylaxis for graft-versus-host disease. Biol Blood Marrow Transplant 2015; 21: 197–198.
Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP et al. Severe cytokine release syndrome following T-cell replete peripheral blood haploidentical donor transplant is associated with poor survival and anti-IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transplant 2016; 22: 1851–1860.
Holtzman NG, Badros A, Kocoglu M, Landau M, Minas NM, Nishioka J et al. Tocilizumab is effective therapy for cytokine release syndrome after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Biol Blood Marrow Transplant 2016; 22: S324.
Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1835–1844.
Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.
Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014; 20: 890–895.
Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Halwani AS et al. Safety and efficacy of allogeneic hematopoetic stem cell transplant (HSCT) after treatment with programmed cell death 1 (PD-1) inhibitors. Blood 2015; 126: 2018–2018.
Acknowledgements
This research was supported in part by NIH/NCI Cancer Center Support Grant P30 CA008748. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Cho, C., Perales, M. Rapid identification of cytokine release syndrome after haploidentical PBSC transplantation and successful therapy with tocilizumab. Bone Marrow Transplant 51, 1620–1621 (2016). https://doi.org/10.1038/bmt.2016.229
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.229
This article is cited by
-
Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide
Annals of Hematology (2021)
-
Tocilizumab in transplantation
European Journal of Clinical Pharmacology (2020)
-
Cytokine release syndrome
Journal for ImmunoTherapy of Cancer (2018)
-
Fludarabine/melphalan/thiotepa
Reactions Weekly (2017)